Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Cancer statistics, 2015

Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

Hsi, E. D., Steinle, R., Balasa, B., Szmania, S. M., Draksharapu, A., Shum, B. P., Huseni, M. A., Powers, D., Nanisetti, A., Zhang, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4246 · Cited by 558

SLAM Family Receptors and SAP Adaptors in Immunity

Cannons, J. L., Tangye, S. G., & Schwartzberg, P. L. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101302 · Cited by 502

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

Tai, Y., Dillon, M., Song, W., Leiba, M., Li, X.-F., Burger, P., Lee, A. I., Podar, K., Hideshima, T., Rice, A. G., et al. (2007) · Blood · doi:10.1182/blood-2007-08-107292 · Cited by 472

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

Voskens, C., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 465

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

Dimopoulos, M. A., Chen, C. L., Spencer, A. G., Niesvizky, R., Attal, M., Stadtmauer, E. A., Petrucci, M. T., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2009) · Leukemia · doi:10.1038/leu.2009.147 · Cited by 366

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

Collins, S. M., Bakan, C. E., Swartzel, G. D., Hofmeister, C. C., Efebera, Y. A., Kwon, H., Starling, G. C., Ciarlariello, D., Bhaskar, S., Briercheck, E. L., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1493-8 · Cited by 296

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

Richardson, P. G. G., Baz, R., Wang, M. L., Jakubowiak, A. J., Laubach, J. P., Harvey, R. D., Talpaz, M., Berg, D. T., Liu, G., Jiang, Y., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548826 · Cited by 202

EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase Cγ, Ca++, and Erk, leading to granule polarization

Pérez‐Quintero, L., Roncagalli, R., Guo, H., Latour, S., Davidson, D., & Veillette, A. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20132038 · Cited by 93

New Developments in Myeloma Treatment and Response Assessment

Kraeber‐Bodéré, F., Jamet, B., Bezzi, D., Zamagni, E., Moreau, P., & Nanni, C. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264972 · Cited by 21

Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma

Dutta, A. K., Hewett, D. R., Fink, J. L., Grady, J. P., & Zannettino, A. C. W. (2017) · British Journal of Haematology · doi:10.1111/bjh.14649 · Cited by 22

Safety of ixazomib for the treatment of multiple myeloma

Bonnet, A., & Moreau, P. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1344212 · Cited by 23

Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model

Menssen, H. D., Harnack, U., Erben, U., Neri, D., Hirsch, B., & Dürkop, H. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2564-6 · Cited by 21

ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING

Taniwaki, M., Yoshida, M., Matsumoto, Y., Shimura, K., Kuroda, J., & Kaneko, H. (2018) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2018.014 · Cited by 21

Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist

Wildes, T. M., & Anderson, K. C. (2018) · Hematology · doi:10.1182/asheducation-2018.1.88 · Cited by 21

Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population

Zanwar, S., Abeykoon, J. P., & Kapoor, P. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00500-4 · Cited by 22

Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses

Musto, P., & Rocca, F. L. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1740084 · Cited by 22

Targeting Nuclear Export Proteins in Multiple Myeloma Therapy

Theodoropoulos, N., Lancman, G., & Chari, A. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00758-2 · Cited by 23

Targeted Therapies for Multiple Myeloma

Leow, C. C.-Y., & Low, M. S. Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050334 · Cited by 21

Anaplastic Multiple Myeloma: An Aggressive Variant With a Poor Response to Novel Therapies

Ammannagari, N., Celotto, K., Neppalli, V. T., Lee, K. P., & Holstein, S. A. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.06.008 · Cited by 21

Potential of NK cells in multiple Myeloma therapy

Khan, A., Devarakonda, S. S., Bumma, N., Chaudhry, M., & Benson, D. M. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1617128 · Cited by 21

Immunotherapy in Multiple Myeloma—Time for a Second Major Paradigm Shift

Mohan, M., Hari, P., & Dhakal, B. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00032 · Cited by 21

Risk of infections in multiple myeloma. A populationbased study on 8,672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry

Blimark, C. H., Carlson, K. E., Day, C., Einarsdottir, S., Juliusson, G., Karma, M., Knut‐Bojanowska, D., Larfors, G., Turesson, I., Villegas-Scivetti, M., et al. (2024) · Haematologica · doi:10.3324/haematol.2024.285645 · Cited by 20

Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting

Zhang, K., Desai, A. P., Zeng, D., Gong, T., Lu, P., & Wang, M. L. (2016) · Oncotarget · doi:10.18632/oncotarget.13314 · Cited by 20

New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib

Richardson, P. G. G., Kumar, S. K., Laubach, J. P., Paba‐Prada, C. E., Gupta, N., Berg, D. T., de Velde, H. J. V., & Moreau, P. (2017) · Journal of Blood Medicine · doi:10.2147/jbm.s102328 · Cited by 20

Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date

Richter, J. R., Sanchez, L. J., & Thibaud, S. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.04.004 · Cited by 20

Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma

Lecat, C. S. Y., Taube, J. B., Wilson, W., Carmichael, J., Parrish, C., Wallis, G., Kyriakou, C. A., Lee, L. S. H., Mahmood, S., Papanikolaou, X. D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703233 · Cited by 20

Isatuximab for Relapsed/Refractory Multiple Myeloma: Review of Key Subgroup Analyses from the Phase III ICARIA-MM Study

Richardson, P. G. G., Harrison, S. J., Bringhen, S., Schjesvold, F. H., Yong, K., Campana, F., Le-Guennec, S., Macé, S., & Dimopoulos, M. A. (2021) · Future Oncology · doi:10.2217/fon-2021-0568 · Cited by 20

Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma

Luca, F. D., Allegra, A., Chio, C. D., Previti, S., Zappalà, M., & Ettari, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043136 · Cited by 21

Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial

Mai, E. K., Goldschmidt, H., Miah, K., Bertsch, U., Besemer, B., Hänel, M., Krzykalla, J., Fenk, R. R., Schlenzka, J., Munder, M., et al. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00366-6 · Cited by 20

Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd‐line therapy for relapsed and refractory multiple myeloma – a phase II trial

Mey, U., Brugger, W., Schwarb, H., Pederiva, S., Schwarzer, A., Dechow, T. N., Jehner, P., Rauh, J., Taverna, C., Schmid, M., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14481 · Cited by 22

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival

Katodritou, E., Kyrtsonis, M., Delimpasi, S., Kyriakou, D. S., Symeonidis, A. S., Spanoudakis, E., Vasilopoulos, G., Anagnostopoulos, Α., Kioumi, A., Zikos, P., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3361-2 · Cited by 20

SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target

Shi, J., Bodo, J., Zhao, X., Durkin, L. M., Goyal, T., Meyerson, H. J., & Hsi, E. D. (2018) · British Journal of Haematology · doi:10.1111/bjh.15393 · Cited by 20

How I treat elderly patients with plasma cell dyscrasias

Gavriatopoulou, M., Fotiou, D., Ntanasis‐Stathopoulos, I., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2018) · Aging · doi:10.18632/aging.101707 · Cited by 20

The pharmacologic management of multiple myeloma in older adults

Dempsey, J. L., Johns, A. C., Rosko, A. E., & Lazarus, H. M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1577822 · Cited by 20

Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma

Pozzi, S., Bari, A., Pecherstorfer, M., & Vallet, S. (2021) · Cancers · doi:10.3390/cancers13194978 · Cited by 20

T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins

Xu, Y., Salazar, G. T., Zhang, N., & An, Z. (2019) · Antibody Therapeutics · doi:10.1093/abt/tbz001 · Cited by 19

Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice

Gozzetti, A., Raspadori, D., Bacchiarri, F., Sicuranza, A., Pacelli, P., Ferrigno, I., Tocci, D., & Bocchia, M. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030120 · Cited by 19

Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma

Ghai, A., Zheleznyak, A., Mixdorf, M., O’Neal, J., Ritchey, J., Rettig, M. P., DiPersio, J. F., Shokeen, M., & Achilefu, S. A. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05097-y · Cited by 19

Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials

Gentile, M., Vigna, E., Palmieri, S., Galli, M., Derudas, D., Mina, R., Pepa, R. D., Zambello, R., Martino, E. A., Bruzzese, A., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.283251 · Cited by 19

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

Mukhopadhyay, P., Abdullah, H. A., Opalinska, J., Paka, P., Richards, E., Weisel, K. C., Trudel, S., Mateos, M., Dimopoulos, M. A., & Lonial, S. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01212-0 · Cited by 21

Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis

Malard, F., Harousseau, J., & Mohty, M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.005 · Cited by 19

Signaling lymphocyte activation molecule family in systemic lupus erythematosus

Comte, D., Karampetsou, M. P., Humbel, M., & Tsokos, G. C. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.11.001 · Cited by 19

The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT / UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial

Cook, G., Royle, K., O’Connor, S. J. M., Cairns, D. A., Ashcroft, A. J., Williams, C. D., Hockaday, A., Cavenagh, J. D., Snowden, J. A., Ademokun, D., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15782 · Cited by 19

Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma

Ailawadhi, S., DerSarkissian, M., Duh, M. S., Lafeuille, M.-H., Posner, G., Ralston, S., Zagadailov, E. A., Ba-Mancini, A., & Rifkin, R. M. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.01.009 · Cited by 20

The effect of novel therapies in high-molecular-risk multiple myeloma.

Lancman, G., Tremblay, D. A., Barley, K. M., Barlogie, B., Cho, H. J., Jagannath, S., Madduri, D., Moshier, E. L., Parekh, S. S., & Chari, A. (2017) · PubMed · Cited by 19

Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma

Hoylman, E., Brown, A. B., Perissinotti, A. J., Marini, B. L., Pianko, M. J., Ye, J. C., Campagnaro, E. L., & Nachar, V. R. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1688324 · Cited by 19

EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies

Kiesewetter, B., Cherny, N. I., Boissel, N., Cerisoli, F., Dafni, U. G., de Vries, E. G. E., Ghia, P., Gökbuget, N., González‐Calle, V., Huntly, B. J. P., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000611 · Cited by 19

Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma

Bilich, T., Nelde, A., Bauer, J., Walz, S., Roerden, M., Salih, H. R., Weisel, K. C., Besemer, B., Marcu, A., Lübke, M., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0288-3 · Cited by 20

Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study

Sunami, K., Suzuki, K., Ri, M., Matsumoto, M., Shimazaki, C., Asaoku, H., Shibayama, H., Ishizawa, K., Takamatsu, H., Ikeda, T., et al. (2020) · Cancer Science · doi:10.1111/cas.14657 · Cited by 19

Immunotherapy of Multiple Myeloma: Promise and Challenges

Abramson, H. N. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s306103 · Cited by 19

Hematologic Malignancies: Plasma Cell Disorders

Dhodapkar, M. V., Borrello, I., Cohen, A. D., & Stadtmauer, E. A. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175546 · Cited by 20

Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study

Cella, D. F., McKendrick, J., Kudlac, A., Palumbo, A. P., Oukessou, A., Vij, R., Zyczynski, T. M., & Davis, C. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3469-4 · Cited by 19

A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche

Solimando, A. G., Vacca, A., & Ribatti, D. (2020) · Journal of Oncology · doi:10.1155/2020/6820241 · Cited by 19

Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins

Magarotto, V., Salvini, M., Bonello, F., Bringhen, S., & Palumbo, A. P. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1102245 · Cited by 18

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

Boyiadzis, M. M., Bishop, M., Abonour, R., Anderson, K. C., Ansell, S. M., Avigan, D., Barbarotta, L., Barrett, A. J., van Besien, K., Bergsagel, P. L., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0188-z · Cited by 18

Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS)

Touzeau, C., Quignot, N., Meng, J., Jiang, H., Khachatryan, A., Singh, M., Taieb, V., Chauny, J.-V., & Désaméricq, G. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04522-y · Cited by 18

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma

Baertsch, M., Fougereau, M., Hielscher, T., Sauer, S., Breitkreutz, I., Jordan, K., Müller‐Tidow, C., Goldschmidt, H., Raab, M., Hillengaß, J., et al. (2021) · Cancers · doi:10.3390/cancers13184706 · Cited by 18

A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma

Seefat, M. R., Cucchi, D. G. J., Dirven, S., Groen, K., Zweegman, S., & Blommestein, H. M. (2021) · Cancers · doi:10.3390/cancers13225606 · Cited by 18

Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma

Miller, K. C., Hashmi, H., & Rajeeve, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1398902 · Cited by 19

Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy

Gonsalves, W. I., Rajkumar, S. V., Gertz, M. A., Dispenzieri, A. A., Lacy, M. Q., Buadi, F. K., Dingli, D., Go, R. S., Leung, N., Kapoor, P., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.91 · Cited by 18

Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma

Maybury, B. D., Cook, G., Pratt, G., Yong, K., & Ramasamy, K. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.06.004 · Cited by 19

How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma

Hofmeister, C. C., & Lonial, S. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.5908 · Cited by 18

Advances in immunotherapy in multiple myeloma

Boussi, L. S., & Niesvizky, R. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000407 · Cited by 18

Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy

Danhof, S., Strifler, S., Hose, D., Kortüm, K. M., Bittrich, M., Hefner, J., Einsele, H., Knop, S. T., & Schreder, M. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2807-1 · Cited by 18

New targets and technologies for CAR-T cells

Freitag, F., Maucher, M., Riester, Z., & Hudecek, M. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000653 · Cited by 20

Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis

Arcuri, L. J., & Américo, A. D. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04404-3 · Cited by 18

Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma

Blommestein, H. M., Franken, M. G., van Beurden-Tan, C. H. Y., Blijlevens, N. M. A., Huijgens, P. C., Sonneveld, P., Groot, C. A. U., & Zweegman, S. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.3497 · Cited by 18

Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma

Mynott, R. L., & Wallington-Beddoe, C. T. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00074 · Cited by 20

Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021

Efficace, F., Cottone, F., Sparano, F., Caocci, G., Vignetti, M., & Chakraborty, R. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.01.009 · Cited by 19

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies

Willenbacher, W., Seeber, A., Steiner, N., Willenbacher, E., Gatalica, Z., Swensen, J. J., Kimbrough, J., & Vranić, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072087 · Cited by 21

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

Bruzzese, A., Derudas, D., Galli, M., Martino, E. A., Rocco, S., Conticello, C., Califano, C., Giuliani, N., Mangiacavalli, S., Farina, G., et al. (2022) · Hematological Oncology · doi:10.1002/hon.3031 · Cited by 17

Daratumumab and isatuximab differentially affect CD38 detection on plasma cells in myeloma: Anti‐ CD38 nanobody (clone JK36 ) and CD319 combination improve flow cytometric identification of plasma cells after targeted therapies

Shameli, A., Catey, T., Woodings, V., Koepke, O., Fromm, J. R., & Cherian, S. (2025) · British Journal of Haematology · doi:10.1111/bjh.20218 · Cited by 17

Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma

Reina-Ortiz, C., Giraldos, D., Azaceta, G., Palomera, L., Marzo, I., Naval, J., Villalba, M., & Anel, A. (2022) · Cells · doi:10.3390/cells11030392 · Cited by 18

The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma

Sellin, M., Berg, S. A., Hagen, P. A., & Zhang, J. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101448 · Cited by 17

Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies

Fatoki, R. A., Koehn, K., Kelkar, A. H., Hadidi, S. A., Mehra, N., Mian, H. S., Landgren, O., Kazandjian, D. G., Hoffman, J. E., Sborov, D. W., et al. (2022) · JCO Global Oncology · doi:10.1200/go.22.00119 · Cited by 18

Difficult‐to‐treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results

Raab, M. S., Zamagni, E., Manier, S., Rodríguez‐Otero, P., Schjesvold, F. H., & Broijl, A. (2023) · eJHaem · doi:10.1002/jha2.743 · Cited by 17

Continuous treatment with lenalidomide and low‐dose dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial

Lu, J., Lee, J. H., Huang, S., Qiu, L., Lee, J., Liu, T., Yoon, S., Kım, K., Shen, Z. X., Eom, H., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14465 · Cited by 17

Talin-1 interaction network promotes hepatocellular carcinoma progression

Chen, P., Zheng, X., Zhou, Y., Xu, Y., Zhu, L., & Qian, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.14674 · Cited by 17

EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells

Rocca, F. L., Airoldi, I., Carlo, E. D., Marotta, P., Falco, G., Simeon, V., Laurenzana, I., Trino, S., Luca, L. D., Todoerti, K., et al. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0338-4 · Cited by 17

Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure

Alhuraiji, A., Naqvi, K., Huh, Y. O., Ho, C., Verstovšek, S., & Bose, P. (2017) · Clinical Case Reports · doi:10.1002/ccr3.1264 · Cited by 17

Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient

Ghobrial, I., Cruz, C. H., Garfall, A. L., Shah, N. D., Munshi, N. C., Kaufman, J. L., Boise, L., Morgan, G. J., Adalsteinsson, V. A., Manier, S., et al. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.02.004 · Cited by 17

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma

Palma, B. D., Marchica, V., Catarozzo, M. T., Giuliani, N., & Accardi, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9093022 · Cited by 17

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

Leleu, X. P., Beksaç, M., Chou, T., Dimopoulos, M. A., Yoon, S., Prince, H. M., Pour, L., Shelekhova, T. V., Chari, A., Khurana, M., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1832672 · Cited by 17

Risk and Response-Adapted Treatment in Multiple Myeloma

Cazaubiel, T., Mulas, O., Montes, L., Schavgoulidze, A., Avet‐Loiseau, H., Corre, J., & Perrot, A. (2020) · Cancers · doi:10.3390/cancers12123497 · Cited by 20

Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma

Yuan, K., Kuang, W., Chen, W., Ji, M., Min, W., Zhu, Y., Hou, Y., Wang, X., Li, J., Wang, L., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114024 · Cited by 17

The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches

Lagreca, I., Riva, G., Nasillo, V., Barozzi, P., Castelli, I., Basso, S., Bettelli, F., Giusti, D., Cuoghi, A., Bresciani, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095242 · Cited by 18

Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma

Fotiou, D., Dimopoulos, M. A., & Kastritis, E. (2022) · Cancers · doi:10.3390/cancers14246216 · Cited by 17

Treatment patterns and clinical outcomes in high‐risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi‐center retrospective study

Cohen, Y. C., Saranga, A., Gatt, M. E., Lavi, N., Ganzel, C., Magen, H., Avivi, I. M., Tadmor, T., Suriu, C., Dolberg, O. J., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25098 · Cited by 17

In silico Identification of HDAC Inhibitors for Multiple Myeloma: A Structure-based Virtual Screening, Drug Likeness, ADMET Profiling, Molecular Docking, and Molecular Dynamics Simulation Study

Debnath, A., Mazumder, R., Mazumder, A., Singh, R. K., & Srivastava, S. (2023) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666230125102954 · Cited by 16

Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma

Najjar, M., McCarron, J., Cliff, E. R. S., Berger, K., Steensma, D. P., Hadidi, S. A., Chakraborty, R., Goodman, A. M., Anto, E., Greene, T., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.42195 · Cited by 16

Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma

Lonial, S., Kaufman, J. L., Reece, D. E., Mateos, M., Laubach, J. P., & Richardson, P. G. G. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1221920 · Cited by 16

Carfilzomib boosted combination therapy for relapsed multiple myeloma

Steiner, R. E., & Manasanch, E. E. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s102756 · Cited by 16

Novel investigational drugs active as single agents in multiple myeloma

D’Agostino, M., Salvini, M., Palumbo, A. P., Larocca, A., & Gay, F. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1324571 · Cited by 16

Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan

Kubo, K., Hori, M., Ohta, K., Handa, H., Hatake, K., Matsumoto, M., Hagiwara, S., Ohashi, K., Nakaseko, C., Suzuki, K., et al. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02757-0 · Cited by 16

Advancements in nanotechnology for the diagnosis and treatment of multiple myeloma

Zhong, W., Zhang, X., Zhao, M., Wu, J., & Lin, D. (2020) · Biomaterials Science · doi:10.1039/d0bm00772b · Cited by 16

Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients

Bonello, F., Boccadoro, M., & Larocca, A. (2020) · Cancers · doi:10.3390/cancers12113106 · Cited by 16

Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity

Suzuki, K., Nishiwaki, K., & Yano, S. (2021) · Cancers · doi:10.3390/cancers13194867 · Cited by 16

New pharmacotherapy options for multiple myeloma

Mina, R., Cerrato, C., Bernardini, A., Aghemo, E., & Palumbo, A. P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1115016 · Cited by 17

New monoclonal antibodies on the horizon in multiple myeloma

O’Donnell, E., & Raje, N. S. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716682490 · Cited by 16

Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens

Maymani, H., Lin, P. Y., Saliba, R. M., Popat, U., Bashir, Q., Shah, N. D., Patel, K. K., Parmar, S., Kebriaei, P., Hosing, C. M., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.01.009 · Cited by 16

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma

Friend, R. N., Bhutani, M., Voorhees, P. M., & Usmani, S. Z. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s98053 · Cited by 16

Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors

Driscoll, J. J., & Brailey, M. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9698-5 · Cited by 16

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma

Cho, S., Lin, L., Xing, L., Yu, T., Wen, K., Anderson, K. C., & Tai, Y. (2017) · Antibodies · doi:10.3390/antib6040018 · Cited by 16

Pharmacological Management of IgG4-Related Disease: From Traditional to Mechanism-Based Targeted Therapies

Akiyama, M., Alshehri, W., Saito, K., Takeuchi, T., & Kaneko, Y. (2025) · Drugs & Aging · doi:10.1007/s40266-024-01172-3 · Cited by 15

Human Atypical B Cells. An Overview

Sanz, I. (2025) · Immunological Reviews · doi:10.1111/imr.70058 · Cited by 17

Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial

Ailawadhi, S., Mikhael, J. R., LaPlant, B. R., Laumann, K. M., Kumar, S. K., Roy, V., Dingli, D., Bergsagel, P. L., Buadi, F. K., Rajkumar, S. V., et al. (2017) · Leukemia · doi:10.1038/leu.2017.258 · Cited by 15

Monoclonal Antibodies in the Treatment of Multiple Myeloma

van de Donk, N. W. C. J., & Zweegman, S. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.002 · Cited by 16

Potential therapeutic targets in plasma cell disorders: A flow cytometry study

Lisenko, K., Schönland, S. O., Hegenbart, U., Wallenwein, K., Braun, U., Mai, E. K., Hillengaß, J., Goldschmidt, H., Jauch, A. S., Ho, A. D., et al. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21351 · Cited by 15

Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma

Lamb, Y. N. (2018) · Drugs · doi:10.1007/s40265-018-0969-4 · Cited by 14

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

Dimopoulos, M. A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M., Leleu, X. P., LeBlanc, R., Suzuki, K., Raab, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805762 · Cited by 540

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Lonial, S., Jakubowiak, A. J., Jagannath, S., Raab, M. S., Facon, T. T. F., Vij, R., Moreau, P., Reece, D. E., White, D. J., Benboubker, L., et al. (2011) · Blood · doi:10.1182/blood.v118.21.303.303 · Cited by 12

Elotuzumab reduces risk of multiple myeloma progression

(2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.115

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma

Yee, A. J., Laubach, J. P., Campagnaro, E. L., Lipe, B. C., Nadeem, O., Friedman, R. S., Cole, C. E., O’Donnell, E., Bianchi, G., Branagan, A. R., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014717 · Cited by 10